Cravath’s New York Office Moves to Two Manhattan West
Senior Attorney, Executive Compensation and Benefits
Arian Mossanenzadeh focuses his practice on executive compensation and employee benefit matters, principally in connection with mergers and acquisitions, securities offerings and other corporate transactions.
Mr. Mossanenzadeh’s notable transactions include representing:
Mr. Mossanenzadeh was born in Tehran, Iran. He received a B.A. magna cum laude with distinction from the University of Washington in 2008, where he was elected to Phi Beta Kappa, and a J.D. from the University of Virginia School of Law in 2013, where he was a senior editorial board member of the Virginia Journal of International Law. Mr. Mossanenzadeh joined Cravath in 2021 and was elected a senior attorney in 2023. Prior to joining Cravath, he was associated with a law firm in New York.
Mr. Mossanenzadeh’s notable transactions include representing:
Mr. Mossanenzadeh was born in Tehran, Iran. He received a B.A. magna cum laude with distinction from the University of Washington in 2008, where he was elected to Phi Beta Kappa, and a J.D. from the University of Virginia School of Law in 2013, where he was a senior editorial board member of the Virginia Journal of International Law. Mr. Mossanenzadeh joined Cravath in 2021 and was elected a senior attorney in 2023. Prior to joining Cravath, he was associated with a law firm in New York.
Deals & Cases
April 04, 2024
On April 3, 2024, The Walt Disney Company (“Disney”) announced that, based on the tabulation of its proxy solicitor, it appears that Disney’s full slate of 12 directors has been elected by a substantial margin over the nominees of Trian and Blackwells at Disney’s 2024 Annual Meeting of Shareholders. Cravath is representing Disney in connection with this matter.
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Deals & Cases
February 12, 2024
On February 12, 2024, Martin Marietta Materials, Inc. (“Martin Marietta”) announced that on February 11, 2024, it entered into a definitive agreement to acquire 20 active aggregates operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia from affiliates of Blue Water Industries LLC (“BWI Southeast”) for $2.05 billion in cash. Additionally, on February 9, 2024, Martin Marietta completed its previously announced divestiture of its South Texas cement and related concrete operations to CRH Americas Materials, Inc., a subsidiary of CRH plc, for $2.1 billion in cash. Cravath is representing Martin Marietta in connection with the transactions.
Deals & Cases
January 31, 2024
On January 31, 2024, Health Care Service Corporation (“HCSC”), the country’s largest customer‑owned health insurer, announced that it has signed a definitive agreement with The Cigna Group (“Cigna”) to acquire its Medicare Advantage, Medicare Supplemental Benefits, Medicare Part D and CareAllies businesses for a purchase price of $3.3 billion. Cigna’s Medicare plans currently serve 3.6 million Medicare members. Cravath is representing HCSC in connection with the transaction.
Firm News
June 15, 2023
On June 15, 2023, Sarah W. Colangelo, Rebecca J. Schindel and Kiran Sheffrin have become of counsels and Aaron S. Cha and Arian Mossanenzadeh have become senior attorneys of the Firm.
Arian Mossanenzadeh focuses his practice on executive compensation and employee benefit matters, principally in connection with mergers and acquisitions, securities offerings and other corporate transactions.
Mr. Mossanenzadeh’s notable transactions include representing:
Mr. Mossanenzadeh was born in Tehran, Iran. He received a B.A. magna cum laude with distinction from the University of Washington in 2008, where he was elected to Phi Beta Kappa, and a J.D. from the University of Virginia School of Law in 2013, where he was a senior editorial board member of the Virginia Journal of International Law. Mr. Mossanenzadeh joined Cravath in 2021 and was elected a senior attorney in 2023. Prior to joining Cravath, he was associated with a law firm in New York.
Mr. Mossanenzadeh’s notable transactions include representing:
Mr. Mossanenzadeh was born in Tehran, Iran. He received a B.A. magna cum laude with distinction from the University of Washington in 2008, where he was elected to Phi Beta Kappa, and a J.D. from the University of Virginia School of Law in 2013, where he was a senior editorial board member of the Virginia Journal of International Law. Mr. Mossanenzadeh joined Cravath in 2021 and was elected a senior attorney in 2023. Prior to joining Cravath, he was associated with a law firm in New York.
Deals & Cases
April 04, 2024
On April 3, 2024, The Walt Disney Company (“Disney”) announced that, based on the tabulation of its proxy solicitor, it appears that Disney’s full slate of 12 directors has been elected by a substantial margin over the nominees of Trian and Blackwells at Disney’s 2024 Annual Meeting of Shareholders. Cravath is representing Disney in connection with this matter.
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Deals & Cases
February 12, 2024
On February 12, 2024, Martin Marietta Materials, Inc. (“Martin Marietta”) announced that on February 11, 2024, it entered into a definitive agreement to acquire 20 active aggregates operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia from affiliates of Blue Water Industries LLC (“BWI Southeast”) for $2.05 billion in cash. Additionally, on February 9, 2024, Martin Marietta completed its previously announced divestiture of its South Texas cement and related concrete operations to CRH Americas Materials, Inc., a subsidiary of CRH plc, for $2.1 billion in cash. Cravath is representing Martin Marietta in connection with the transactions.
Deals & Cases
January 31, 2024
On January 31, 2024, Health Care Service Corporation (“HCSC”), the country’s largest customer‑owned health insurer, announced that it has signed a definitive agreement with The Cigna Group (“Cigna”) to acquire its Medicare Advantage, Medicare Supplemental Benefits, Medicare Part D and CareAllies businesses for a purchase price of $3.3 billion. Cigna’s Medicare plans currently serve 3.6 million Medicare members. Cravath is representing HCSC in connection with the transaction.
Firm News
June 15, 2023
On June 15, 2023, Sarah W. Colangelo, Rebecca J. Schindel and Kiran Sheffrin have become of counsels and Aaron S. Cha and Arian Mossanenzadeh have become senior attorneys of the Firm.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.